PND27 - COST IMPLICATIONS IN THE SELECTION OF FIRST LINE TREATMENT FOR HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL
Oct 1, 2018, 00:00 AM
10.1016/j.jval.2018.09.1994
https://www.valueinhealthjournal.com/article/S1098-3015(18)35296-3/fulltext
Section Title :
Section Order :
1348
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35296-3&doi=10.1016/j.jval.2018.09.1994